A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure

Singapore Medical Journal

Volumn 44, Issue 2, 2003, Pages 74-78

  Mak, Siu Ka ^a   Loo, C K ^a   Wong, P N ^a   Lo, K Y ^a   Tong, G M W ^a   Lam, E K M ^a   Wong, A K M ^a  

^a KWONG WAH HOSPITAL   (Hong Kong)

Author keywords

Chronic renal failure; Eradication; Helicobacter pylori; Triple therapy

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; CREATININE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPIC SURGERY; ENZYME ASSAY; ERADICATION THERAPY; EVALUATION; FEMALE; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; MALE; NEPHROTOXICITY; PEPTIC ULCER; RAPID UREASE TEST; SHORT COURSE THERAPY; SIDE EFFECT; ULCER HEALING;

AGED; AMOXICILLIN; ANTI-ULCER AGENTS; CLARITHROMYCIN; CREATININE; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; OMEPRAZOLE; PENICILLINS; PEPTIC ULCER; RETROSPECTIVE STUDIES;

EID: 0037302894     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr, Saeed ZA, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. Ann Intern Med 1992; 116:705-8.
2. Triebling AT, Korsten MA, Dlugosz JW, Paronetto F, Lieber CS. Severity of Helicobacter-induced gastric injury correlates with gastric juice ammonia. Dig Dis Sci 1991; 36:1089-96.
3. Ala-Kaila K, Vaajalahti P, Karvonen AL, Kokki M. Gastric Helicobacter and upper gastrointestinal symptoms in chronic renal failure. Ann Med 1991; 23:403-6.
4. Muñoz de Bustillo E, Sánchez Tomero JA, Sanz JC, Moreno JA, Jiménez, López-Brea M, et al. Eradication and follow-up of Helicobacter pylori infection in hemodialysis patients. Nephron 1998; 79:55-60.
5. Rowe PA, El Nujumi AM, Williams C, Dahill S, Briggs JD, McColl KEL. The diagnosis of Helicobacter pylori infection in uremic patients. Am J Kidney Dis 1992; 20:574-9.
6. Lam SK, Ching CK, Lai KC, Wong BC, Lai CL, Chan CK, et al. Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997; 41:43-8.
7. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol 1994; 89:1785-8.
8. Uemura N, Mukai T, Okamoto S, Yamaguchi S, Mashiba H, Taniyama K, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6:639-42.
9. Burette A, Glupczynski Y, De Prez C. Evaluation of various multi-drug eradication regimens for Helicobacter pylori. Eur J Gastroenterol Hepatol 1992; 4:817-23.
10. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493-6.
11. Lind T, Mégraud F, Unge P, Bayerdörffer E, O'Morain C, Spiller R, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116:248-53.
12. Nakao M, Malfertheiner P. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori. Helicobacter 1998; 3:21-7.
13. Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lucker PW, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Methods Find Exp Clin Pharmacol 1995; 17:489-95.
14. Tamura H, Tokushima H, Murakawa M, Matsumura O, Itoyama S, Sekine S, et al. Eradication of Helicobacter pylori in patients with end-stage renal disease under dialysis treatment. Am J Kidney Dis 1997; 29:86-90.
15. Price AB. The Sydney System: Histological division. J Gastroenterol Hepatol 1991; 6:209-22.
16. Lau CF, Wong MC, Yee KS, Loo CK, Lam KM. Evaluation of an economical, home-made rapid urease test for the detection of Helicobacter pylori infection in an ex-subvented hospital. Proceedings of the Tenth Asian-Pacific Congress of Gastroenterology, Yokohama, Japan, 1996; p 188.
17. Peterson WL, Helicobacter pylori and peptic ulcer disease. N Engl J Med 1991; 324:1043-8.
18. Forman D. Helicobacter pylori and gastric cancer. Scand J Gastroenterol 1996; 31 (Suppl 220):23-6.
19. Milito G, Taccone-Gallucci M, Brancaleone C, Nardi F, Cesca D, Boffo V, et al. The gastrointestinal tract in uremic patients on long-term hemodialysis. Kidney Int 1985; 28 (Suppl 17):S157-60.
20. Andriulli A, Malfi B, Recchia S, Ponti V, Triolo G, Segoloni G. Patients with chronic renal failure are not at a risk of developing chronic peptic ulcers. Clin Nephrol 1985; 23:245-8.
21. The European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41:8-13.
22. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93:2330-8.
23. 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture and ELISA serology. Gut 1991; 32:1461-4.
24. Labenz J, Stolte M, Peitz U, Tillenburg B, Becker T, Borsch G. One-week triple therapy with omeprazole, amoxicillin, and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1996; 10:207-10.
25. Lerang F, Moum B, Haug JB, Tolås P, Breder O, Aubert E, et al. Highly effective twice-daily triple therapies for Helicobacter infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterology 1997; 92:248-53.
26. Ching CK, Leung KP, Yung RWH, Lam SK, Wong BCY, Lai KC, et al. Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. Gut 1996; 38:675-8.
27. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin - influence on treatment outcome. Am J Gastroenterol 1998; 93:386-9.
28. Mégraud F. Adjuvant therapy for Helicobacter pylori eradication: Role of lansoprazole shown in vitro. J Clin Gastroenterol 1995; 20 (Suppl 1):S24-7.
29. Gladziwa U, Koltz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994; 27:393-408.
30. 14C] omeprazole in patients with impaired renal function, Clin Pharmacol Ther 1986; 40:344-51.
31. Delhotal-Landes B, Flouvat B, Duchier J, Molinie P, Dellatolas F, Lemaire M. Pharmacokinetics of Lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993; 45:367-71.
32. Arancibia A, Droguett MT, Fuentes G, Gonzalez G, Gonzalez C, Thambo S, et al. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function. Int J Clin Pharmacol Ther Toxicol 1982; 20:447-53.
33. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74:613-34.
34. Sung JJY. Where are we with current therapy? Helicobacter 2000; 5 (Suppl 1):S17-21.